Resource Type

Journal Article 3

Year

2022 1

2020 1

2015 1

Keywords

Cerenkov luminescence imaging 1

anti-angiogenesis 1

artificial intelligence 1

check point inhibitor 1

clinical big data 1

common data model 1

hepatocellular carcinoma 1

intraoperative image-guided surgery 1

management system 1

multimodality molecular imaging 1

natural language processing 1

oncology 1

optical molecular imaging 1

optical multimodality tomography 1

tyrosine kinase inhibitor 1

open ︾

Search scope:

排序： Display mode:

Medical oncology management of advanced hepatocellular carcinoma 2019: a reality check

Amy Lee, Fa-Chyi Lee

Frontiers of Medicine 2020, Volume 14, Issue 3,   Pages 273-283 doi: 10.1007/s11684-019-0728-2

Abstract: In terms of global cancer-related deaths, hepatocellular carcinoma (HCC) has the fourth highest mortality rate. Up until 2017, treatment of advanced HCC was largely limited to sorafenib, an oral tyrosine kinase inhibitor, with little to no success in the development of alternative treatment options. However, in the past two years, there has been an unprecedented increase in both the number and type of treatment options available for HCC. As of 2019, the US FDA has approved four oral tyrosine kinase inhibitors, two immune checkpoint inhibitors, and one anti-angiogenesis antibody for the treatment of HCC. Even with this new variety, systemic treatment of advanced HCC remains largely unsatisfactory, and the median survival rate stands at approximately one year. The expected breakthrough of using immune checkpoint inhibitors in advanced HCC did not materialize in 2019. The use of immune checkpoint inhibitors in conjunction with oral tyrosine kinase inhibitors or anti-angiogenesis medications is the current clinical research trend, the results of which are eagerly anticipated. Despite limited progress in survival, HCC research is currently experiencing a period of growth and innovation, and there is hope for significant advances in the treatment of advanced HCC as the field continues to develop.

Keywords： hepatocellular carcinoma     tyrosine kinase inhibitor     check point inhibitor     anti-angiogenesis    

HTML PDF Collect

Design and Application of Clinical Big Data Management System for Oncology

Ma Lin, Bao Chenlu, Li Qing,Wu Jingyi, Pan Hong’an, Li Pengfei, Zhang Luxia, Zhan Qimin

Strategic Study of CAE 2022, Volume 24, Issue 6,   Pages 127-136 doi: 10.15302/J-SSCAE-2022.06.011

Abstract: Hence, establishing a national clinical big data management system for oncology based on artificialintelligence could potentially promote the application of clinical data in oncology, further improvingthe quality and efficiency of clinical management for oncology.and presented the significant values of an oncology clinical data management system.Considering the complexity of multi-source and multi-modal data in oncology, we explored the possible

Keywords： clinical big data     management system     oncology     artificial intelligence     common data model     natural language    

HTML PDF Collect

Optical Molecular Imaging Frontiers in Oncology: The Pursuit of Accuracy and Sensitivity Review

Kun Wang,Chongwei Chi,Zhenhua Hu,Muhan Liu,Hui Hui,Wenting Shang,Dong Peng,Shuang Zhang,Jinzuo Ye,Haixiao Liu,Jie Tian

Engineering 2015, Volume 1, Issue 3,   Pages 309-323 doi: 10.15302/J-ENG-2015082

Abstract:

Cutting-edge technologies in optical molecular imaging have ushered in new frontiers in cancer research, clinical translation, and medical practice, as evidenced by recent advances in optical multimodality imaging, Cerenkov luminescence imaging (CLI), and optical image-guided surgeries. New abilities allow in vivo cancer imaging with sensitivity and accuracy that are unprecedented in conventional imaging approaches. The visualization of cellular and molecular behaviors and events within tumors in living subjects is improving our deeper understanding of tumors at a systems level. These advances are being rapidly used to acquire tumor-to-tumor molecular heterogeneity, both dynamically and quantitatively, as well as to achieve more effective therapeutic interventions with the assistance of real-time imaging. In the era of molecular imaging, optical technologies hold great promise to facilitate the development of highly sensitive cancer diagnoses as well as personalized patient treatment—one of the ultimate goals of precision medicine.

Keywords： optical molecular imaging     multimodality molecular imaging     optical multimodality tomography     Cerenkov luminescence imaging     intraoperative image-guided surgery    

HTML PDF Collect

Title Author Date Type Operation

Medical oncology management of advanced hepatocellular carcinoma 2019: a reality check

Amy Lee, Fa-Chyi Lee

Journal Article

Design and Application of Clinical Big Data Management System for Oncology

Ma Lin, Bao Chenlu, Li Qing,Wu Jingyi, Pan Hong’an, Li Pengfei, Zhang Luxia, Zhan Qimin

Journal Article

Optical Molecular Imaging Frontiers in Oncology: The Pursuit of Accuracy and Sensitivity

Kun Wang,Chongwei Chi,Zhenhua Hu,Muhan Liu,Hui Hui,Wenting Shang,Dong Peng,Shuang Zhang,Jinzuo Ye,Haixiao Liu,Jie Tian

Journal Article